Sulforaphane-mediated immune regulation through inhibition of NF-kB and MAPK signaling pathways in human dendritic cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study using human cell cultures
PubMed 38945082 · doi:10.1016/j.biopha.2024.117056
What was done
Human dendritic cells were pretreated with sulforaphane (SFN) and subsequently exposed to lipopolysaccharide to mimic a chronic inflammatory environment. The researchers assessed signaling pathway activity (NF-κB, p38 MAPK, and JNK), surface marker expression, cytokine ratios (TNF-α/IL-10), regulatory T-cell (Treg) proliferation, and IL-10 production by B-cells.
What was found
SFN pretreatment inhibited the NF-κB and MAPK (p38 and JNK) pathways in dendritic cells. This led to a slight reduction in surface marker expression, a decrease in the TNF-α/IL-10 ratio, enhanced Treg-cell proliferation, and increased IL-10 production by B-cells. The abstract reports these qualitative directional outcomes without providing specific numerical values, concentrations, or effect sizes.
Why it matters
This study outlines a cellular mechanism by which sulforaphane promotes an anti-inflammatory and immunoregulatory phenotype in human immune cells.
Limits
This is an in vitro bench study without in vivo validation; physiological relevance, oral bioavailability, and clinical dosing remain unaddressed. The abstract does not report the number of biological donors (n), tested concentrations, or exact statistical metrics.
Cited by
- supports Sulforaphane inhibits the NF-κB inflammatory pathway.